BACKGROUND: Arterial stiffness (AS) is associated, and a predictor of, outcome in patients with cardiovascular and renal disease. AIM: In this study, we estimated glomerular filtration rate (eGFR) and measured indices of AS in patients with suspected coronary artery disease (CAD), and assessed their predictive value on outcome. DESIGN: Prospective cohort study. METHODS: AS was measured using pulse wave velocity (PWV) and pulse wave analysis in patients with no known renal disease who had recently undergone coronary angiography. Renal function was assessed using serum creatinine concentration [creat](sr) and eGFR (Cockcroft & Gault, C&G). The primary endpoint was a combination of hospitalization due to cardiovascular disease and all-cause mortality. RESULTS: Two hundred eighty-four subjects (210 men, 74 women, mean age 62 years) were followed-up for a mean of 1.5 years. PWV was negatively associated with eGFR (r(2) = 0.09, P < 0.001), even in patients with an eGFR > or =60 ml/min/m(2) (r(2) = 0.04, P < 0.01). PWV was determined by age, heart rate, systolic blood pressure, body mass index and [creat](sr) (r(2) = 0.38, P < 0.001). A lower eGFR (P < 0.01), PWV above the median (P < 0.05) and degree of CAD (P < 0.001) predicted a shorter time to the primary endpoint. eGFR and degree of CAD remained independent determinants of outcomes (P < 0.01), even in patients with normal renal function (P < 0.01). CONCLUSION: This study suggests that even minor reductions in eGFR, within the normal range, are an additional independent risk marker in patients with CAD.
BACKGROUND: Arterial stiffness (AS) is associated, and a predictor of, outcome in patients with cardiovascular and renal disease. AIM: In this study, we estimated glomerular filtration rate (eGFR) and measured indices of AS in patients with suspected coronary artery disease (CAD), and assessed their predictive value on outcome. DESIGN: Prospective cohort study. METHODS: AS was measured using pulse wave velocity (PWV) and pulse wave analysis in patients with no known renal disease who had recently undergone coronary angiography. Renal function was assessed using serum creatinine concentration [creat](sr) and eGFR (Cockcroft & Gault, C&G). The primary endpoint was a combination of hospitalization due to cardiovascular disease and all-cause mortality. RESULTS: Two hundred eighty-four subjects (210 men, 74 women, mean age 62 years) were followed-up for a mean of 1.5 years. PWV was negatively associated with eGFR (r(2) = 0.09, P < 0.001), even in patients with an eGFR > or =60 ml/min/m(2) (r(2) = 0.04, P < 0.01). PWV was determined by age, heart rate, systolic blood pressure, body mass index and [creat](sr) (r(2) = 0.38, P < 0.001). A lower eGFR (P < 0.01), PWV above the median (P < 0.05) and degree of CAD (P < 0.001) predicted a shorter time to the primary endpoint. eGFR and degree of CAD remained independent determinants of outcomes (P < 0.01), even in patients with normal renal function (P < 0.01). CONCLUSION: This study suggests that even minor reductions in eGFR, within the normal range, are an additional independent risk marker in patients with CAD.
Authors: Katherine H Michener; Gary F Mitchell; Farzad Noubary; Naya Huang; Tamara Harris; Margret B Andresdottir; Runolfur Palsson; Vilmundur Gudnason; Andrew S Levey Journal: Am J Nephrol Date: 2015-06-06 Impact factor: 3.754
Authors: Merrill F Elias; Adam Davey; Gregory A Dore; Avrum Gillespie; Walter P Abhayaratna; Michael A Robbins Journal: Am J Hypertens Date: 2013-09-30 Impact factor: 2.689
Authors: Yoav Ben-Shlomo; Melissa Spears; Chris Boustred; Margaret May; Simon G Anderson; Emelia J Benjamin; Pierre Boutouyrie; James Cameron; Chen-Huan Chen; J Kennedy Cruickshank; Shih-Jen Hwang; Edward G Lakatta; Stephane Laurent; João Maldonado; Gary F Mitchell; Samer S Najjar; Anne B Newman; Mitsuru Ohishi; Bruno Pannier; Telmo Pereira; Ramachandran S Vasan; Tomoki Shokawa; Kim Sutton-Tyrell; Francis Verbeke; Kang-Ling Wang; David J Webb; Tine Willum Hansen; Sophia Zoungas; Carmel M McEniery; John R Cockcroft; Ian B Wilkinson Journal: J Am Coll Cardiol Date: 2013-11-13 Impact factor: 24.094
Authors: Sabrina H Rossi; Emily P McQuarrie; William H Miller; Ruth M Mackenzie; Jane A Dymott; María U Moreno; Chiara Taurino; Ashley M Miller; Ulf Neisius; Geoffrey A Berg; Zivile Valuckiene; Jonathan A Hannay; Anna F Dominiczak; Christian Delles Journal: BMC Nephrol Date: 2013-08-13 Impact factor: 2.388
Authors: Khai P Ng; Poorva Jain; Gurdip Heer; Val Redman; Odette L Chagoury; George Dowswell; Sheila Greenfield; Nick Freemantle; Jonathan N Townend; Paramjit S Gill; Richard J McManus; Charles J Ferro Journal: Trials Date: 2014-05-06 Impact factor: 2.279
Authors: Mark A Supiano; Laura Lovato; Walter T Ambrosius; Jeffrey Bates; Srinivasan Beddhu; Paul Drawz; Jamie P Dwyer; Naomi M Hamburg; Dalane Kitzman; James Lash; Eva Lustigova; Cynthia M Miracle; Suzanne Oparil; Dominic S Raj; Daniel E Weiner; Addison Taylor; Joseph A Vita; Reem Yunis; Glenn M Chertow; Michel Chonchol Journal: PLoS One Date: 2018-09-26 Impact factor: 3.240